Treatment(s) now being considered-Targeted therapy Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Targeted therapy Posts on Medivizor

A review on new therapies to treat metastatic melanoma

Posted by on Apr 20, 2018 in Melanoma | 0 comments

In a nutshell This study reviewed other studies about different treatments for metastatic (spread to other parts of the body) melanoma. Researchers suggested that targeted therapy improves overall survival of these patients when compared to chemotherapy. Some background Melanoma is the most dangerous common skin cancer. 70 to 80% of patients are...

Read More

Long-term outcomes with dabrafenib combined with trametinib in metastatic melanoma

Posted by on Dec 18, 2017 in Melanoma | 0 comments

In a nutshell This study investigated the long-term safety and effectiveness of dabrafenib (Tafinlar) and trametinib (Mekinist) in metastatic melanoma. Researchers suggested that this treatment increased overall survival in melanoma patients. Some background Some melanoma patients have a mutation (permanent change) in the BRAF gene. Dabrafenib...

Read More

A review in melanoma brain metastasis treatment

Posted by on Nov 18, 2017 in Melanoma | 0 comments

In a nutshell This study reviewed the currently available treatments for melanoma brain metastasis (MBM; spread to the brain). Researchers reported that treatment should be personalized for the different types of patients.  Some background Melanoma has the highest risk of spreading to the brain among all common cancer types. Until the last...

Read More

Dabrafenib combined with trametinib in the treatment of melanoma brain metastasis

Posted by on Aug 21, 2017 in Melanoma | 0 comments

In a nutshell This review examined the effectiveness of dabrafenib (Tafinlar) and trametinib (Mekinist) for BRAF mutated melanoma with brain metastasis. Researchers concluded that this combined treatment is an important therapy option for patients with advanced melanoma. Some background Some melanoma patients have a mutation (permanant change) in...

Read More

Dabrafenib combined with trametinib is associated with durable responses in metastatic melanoma

Posted by on Jun 28, 2017 in Melanoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of combined treatment with dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF mutated stage 3 or 4 melanoma. Researchers suggested that the combination treatment has durable (3 years or more) results.   Some background Patients with metastatic (spread to...

Read More

Vemurafenib combined with cobimetinib is an effective treatment option for BRAF-mutant melanoma

Posted by on Nov 7, 2016 in Melanoma | 0 comments

In a nutshell This study examined the effectiveness and safety of the combined treatment of vemurafenib (Zelboraf) with cobimetinib (Cotellic) in advanced melanoma. Researchers concluded that this combination treatment is an important therapy option for patients with advanced melanoma. Some background Some melanoma patients have a...

Read More

Factors affecting treatment by BRAF inhibitors in melanoma

Posted by on May 2, 2016 in Melanoma | 0 comments

In a nutshell The authors aimed to analyze the factors that could predict resistance to BRAF inhibitor therapy in advanced melanoma. The authors found out that levels of certain proteins and the presence of a type of immune cell could predict the occurrence of resistance.  Some background In advanced melanoma (stages 3 or 4), cancer spreads...

Read More